KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Bionano Genomics (BNGO) Gains from Sales and Divestitures (2025)

Bionano Genomics (BNGO) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $1740.0 as the latest value for Q4 2025.

Quarterly Gains from Sales and Divestitures changed N/A to $1740.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1740.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $1740.0 for FY2025, N/A changed from the prior year.
Gains from Sales and Divestitures hit $1740.0 in Q4 2025 for Bionano Genomics.
In the past five years, Gains from Sales and Divestitures ranged from a high of $1740.0 in Q4 2025 to a low of $1740.0 in Q4 2025.